New drug combo aims to improve ovarian cancer maintenance with fewer dropouts

NCT ID NCT07647653

Not yet recruiting Disease control Sponsor: Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they stay cancer-free. Fluzoparib has shown a much lower treatment discontinuation rate in other studies, suggesting it might be easier to tolerate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluzoparib and bevacizumab
What this could lead to: If fluzoparib works as well as olaparib with fewer side effects, it could offer a new, more tolerable maintenance option for women with HRD-positive advanced ovarian cancer.
What could go wrong: This is an early-phase exploratory study with only 120 participants. Fluzoparib may not prove as effective or safe as olaparib, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.